Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps
Acta Otorhinolaryngologica Italica · 2025
DOI: 10.14639/0392-100x-n2841 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Otorhinolaryngologica Italica, 2025. Verfasst von Letizia Nitro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Body Mass Index, Nasal Polyps, Rhinosinusitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Response to dupilumab for chronic rhinosinusitis with nasal polyps, albeit almost always excellent, is still not predictable. Our study focuses on the role of body mass index (BMI) on the efficacy of dupilumab.
Methods
We present a retrospective multicentre study of 106 patients on dupilumab, stratified in 3 subgroups of BMI. The main therapeutic outcomes investigated were Nasal Polyp Score (NPS), Sino-Nasal-Outcome Test - 22 (SNOT-22), Sniffin' Sticks Identification test and visuo-analogical scale, and the different timing of response, according to De Corso et al. criteria.
Results
Dupilumab treatment led to a progressive improvement for all outcomes at all time points. Comparing the different metabolic subgroups, a late response in terms of decrease in NPS was observed only in 3 obese patients. A significant decrease was also found in SNOT-22 score at 6 and 12 months, which was less marked in overweight/obese patients.
Conclusions
Our study confirmed the efficacy of dupilumab in each BMI subgroup. However, the efficacy seems to follow different timing with respect to patients' BMI. Our data suggest that patients with a compromised metabolic state present more severe disease at baseline and a possibly delayed response to dupilumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, University of Milan, Milan, Italy.
- Otolaryngology Unit - Head and Neck Surgery, A. Gemelli Hospital Foundation IRCCS, Rome, Italy.
- Otolaryngology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- Otorhinolaryngology, Catholic University of The Sacred Heart, Rome, Italy.
Zitieren
APA
Nitro, L., De Corso, E., Borin, M., Saibene, A. M., Arnone, F., Ferella, F., Gramellini, G., Cantiani, A., De Maio, G., Spanu, C., Dragonetti, A. G., Felisati, G., & Pipolo, C. (2025). Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps. Acta Otorhinolaryngologica Italica. https://doi.org/10.14639/0392-100x-n2841
Vancouver
Nitro L, De Corso E, Borin M, Saibene AM, Arnone F, Ferella F, et al. Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps. Acta Otorhinolaryngologica Italica. 2025. doi:10.14639/0392-100x-n2841
BibTeX
@article{Nitro2025,
author = {Nitro, Letizia and De Corso, Eugenio and Borin, Marco and Saibene, Alberto Maria and Arnone, Flavio and Ferella, Francesco and Gramellini, Giulia and Cantiani, Alessandro and De Maio, Gabriele and Spanu, Camilla and Dragonetti, Alberto Giulio and Felisati, Giovanni and Pipolo, Carlotta},
title = {Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps},
journal = {Acta Otorhinolaryngologica Italica},
year = {2025},
doi = {10.14639/0392-100x-n2841}
}
EUVIMED